Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KontRASt-06: JDQ443 in First-line KRAS G12C-mutated NSCLC
NCT05445843Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 2 trial of opnurasib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Dec 2022; status: active, not recruiting.
02
Drugs
opnurasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05445843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445843.